ESSA Pharma Company Insiders
EPIX Stock | USD 1.79 0.02 1.10% |
Slightly above 90 percent of ESSA Pharma's insiders are activelly selling. The analysis of the overall insider sentiment regarding ESSA Pharma suggests that a very large number of insiders are panicking. ESSA Pharma employs about 50 people. The company is managed by 12 executives with a total tenure of roughly 117 years, averaging almost 9.0 years of service per executive, having 4.17 employees per reported executive.
ESSA Pharma's Insider Buying Vs Selling
10
Selling | Buying |
Latest Trades
2024-11-01 | Growth N. V. Biotech | Disposed 7879583 @ 1.53 | View | ||
2024-10-07 | Peter Virsik | Disposed 694 @ 6.03 | View | ||
2024-09-09 | Peter Virsik | Disposed 694 @ 6 | View | ||
2024-09-03 | Peter Virsik | Disposed 2082 @ 6.03 | View | ||
2024-05-06 | Peter Virsik | Disposed 694 @ 6.95 | View | ||
2024-04-05 | Peter Virsik | Disposed 694 @ 7.94 | View | ||
2024-03-05 | Peter Virsik | Disposed 694 @ 8.98 | View | ||
2024-01-16 | Peter Virsik | Disposed 1718 @ 10.01 | View | ||
2024-01-05 | Peter Virsik | Disposed 699 @ 6.11 | View | ||
2023-12-14 | David Ross Parkinson | Acquired 9223 @ 2.3 | View |
Monitoring ESSA Pharma's insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
ESSA |
ESSA Pharma Management Team Effectiveness
The company has return on total asset (ROA) of (0.1479) % which means that it has lost $0.1479 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.1983) %, meaning that it created substantial loss on money invested by shareholders. ESSA Pharma's management efficiency ratios could be used to measure how well ESSA Pharma manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to rise to -1.86 in 2024. Return On Capital Employed is likely to drop to -1.56 in 2024. At this time, ESSA Pharma's Total Assets are fairly stable compared to the past year. Non Current Assets Total is likely to rise to about 383.8 K in 2024, whereas Non Currrent Assets Other are likely to drop slightly above 181.3 K in 2024.Common Stock Shares Outstanding is likely to rise to about 53.2 M in 2024, despite the fact that Net Loss is likely to grow to (30 M).
ESSA Pharma Workforce Comparison
ESSA Pharma is rated # 3 in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 283. ESSA Pharma retains roughly 50.0 in number of employees claiming about 18% of equities under Health Care industry.
ESSA Pharma Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific ESSA Pharma insiders, such as employees or executives, is commonly permitted as long as it does not rely on ESSA Pharma's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, ESSA Pharma insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Parkinson David Ross 2 days ago Acquisition by Parkinson David Ross of 350000 shares of ESSA Pharma at 9.04 subject to Rule 16b-3 | ||
Berger Franklin M over a month ago Disposition of 50000 shares by Berger Franklin M of ESSA Pharma at 2.67 subject to Rule 16b-3 | ||
Virsik Peter over two months ago Disposition of 694 shares by Virsik Peter of ESSA Pharma at 6.0 subject to Rule 16b-3 | ||
Biotech Growth N V over two months ago Disposition of tradable shares by Biotech Growth N V of ESSA Pharma subject to Rule 16b-3 | ||
Virsik Peter over two months ago Acquisition by Virsik Peter of 72782 shares of ESSA Pharma at 3.23 subject to Rule 16b-3 | ||
Bvf Partners L P/il over six months ago Disposition of tradable shares by Bvf Partners L Pil of ESSA Pharma subject to Rule 16b-3 | ||
Virsik Peter over six months ago Disposition of 694 shares by Virsik Peter of ESSA Pharma at 6.95 subject to Rule 16b-3 | ||
Peter Virsik over six months ago Acquisition by Peter Virsik of 110000 shares of ESSA Pharma at 9.04 subject to Rule 16b-3 |
ESSA Pharma Notable Stakeholders
An ESSA Pharma stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as ESSA Pharma often face trade-offs trying to please all of them. ESSA Pharma's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting ESSA Pharma's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
David MD | CEO and President and Director | Profile | |
MS MBA | Executive COO | Profile | |
Erin Rudsinski | Executive | Profile | |
CMA CPA | Chief Officer | Profile | |
Terry Schuenemeyer | Executive | Profile | |
Neil Thapar | Executive | Profile | |
Nkengyal Barber | Executive | Profile | |
Alessandra MD | Chief Officer | Profile | |
Erica Osbourne | Executive | Profile | |
Chandtip Chandhasin | Executive | Profile | |
Loleta Harris | Executive | Profile | |
Steve Pondell | Executive | Profile |
About ESSA Pharma Management Performance
The success or failure of an entity such as ESSA Pharma often depends on how effective the management is. ESSA Pharma management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of ESSA management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the ESSA management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last Reported | Projected for Next Year | ||
Return On Tangible Assets | (1.96) | (1.86) | |
Return On Capital Employed | (1.48) | (1.56) | |
Return On Assets | (1.35) | (1.28) | |
Return On Equity | (1.48) | (1.41) |
Please note, the imprecision that can be found in ESSA Pharma's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of ESSA Pharma. Check ESSA Pharma's Beneish M Score to see the likelihood of ESSA Pharma's management manipulating its earnings.
ESSA Pharma Workforce Analysis
Traditionally, organizations such as ESSA Pharma use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare ESSA Pharma within its industry.ESSA Pharma Manpower Efficiency
Return on ESSA Pharma Manpower
Revenue Per Employee | 0.0 | |
Revenue Per Executive | 0.0 | |
Net Loss Per Employee | 531.6K | |
Net Loss Per Executive | 2.2M | |
Working Capital Per Employee | 2.9M | |
Working Capital Per Executive | 12.1M |
Additional Tools for ESSA Stock Analysis
When running ESSA Pharma's price analysis, check to measure ESSA Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ESSA Pharma is operating at the current time. Most of ESSA Pharma's value examination focuses on studying past and present price action to predict the probability of ESSA Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ESSA Pharma's price. Additionally, you may evaluate how the addition of ESSA Pharma to your portfolios can decrease your overall portfolio volatility.